- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Interventions
- eribulin mesylate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2833–2856
of 4,782
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Laboratory Biomarker Analysis, Lenalidomide, Sonidegib
- Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Glioblastoma, Prostate Cancer, Gynecologic Cancer, Colorectal Cancer, Sarcoma, Kidney Cancer, Bladder Cancer, Lymphoma, Leukemia, Head and Neck Cancer, Pancreas Cancer, Multiple Myeloma, Anxiety, Social Isolation, Stress, Loneliness, Melanoma, Uterine Cancer
- Interventions
- Elly Mobile Phone Application
- Behavioral
- Lead sponsor
- Gillian Gresham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy Adults
- Interventions
- PF-07220060, Itraconazole, Probenecid
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Small Cell Lung Cancer
- Interventions
- RO7051790
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Urothelial Carcinoma
- Interventions
- DR-0202
- Drug
- Lead sponsor
- Dren Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Orlando, Florida • Sarasota, Florida + 7 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- HLX43 DOSE 1 (2.0 mg/kg), HLX43 DOSE 2 (2.5 mg/kg)
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 21
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 15 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- autologous human tumor-derived HSPPC-96
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 39
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more
- Conditions
- Diagnostic Imaging, Neoplasms
- Interventions
- BAY94-9392
- Drug
- Lead sponsor
- Lantheus Biosciences Ltd.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- dexamethasone, lenalidomide, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 2
- States / cities
- Royal Oak, Michigan • Salt Lake City, Utah
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed, Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Las Vegas, Nevada • New York, New York + 1 more
- Conditions
- Multiple Myeloma, Leukemia, MGUS, Monoclonal B-Cell Lymphocytosis
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 1,892 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Large-cell Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Marginal Zone B-cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-cell Lymphoma, Prolymphocytic Leukemia, Bone Marrow Failure Syndromes, Myeloproliferative Neoplasms/Myelofibrosis, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Leukemia or MDS in Aplasia, Relapsed T-Cell Lymphoma, Relapsed Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Fludarabine, Cyclophosphamide, MMF, Sirolimus, TBI, Umbilical cord blood cell infusion, ATG
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Multiple Myeloma, Immune System Diseases
- Interventions
- CAR138 T Cells
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2039
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Interventions
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Alexander City, Alabama • Anchorage, Alaska • Springdale, Arkansas + 5 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelofibrosis, Myeloproliferative Syndrome
- Interventions
- total marrow irradiation, fludarabine phosphate, busulfan, myeloid progenitor cell transplantation, anti-thymocyte globulin, tacrolimus, methotrexate, laboratory biomarker analysis
- Radiation · Drug · Procedure + 2 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Liposarcoma, Metastatic Liposarcoma
- Interventions
- MGCD516
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York
- Conditions
- Solid Malignancies
- Interventions
- CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg)
- Drug
- Lead sponsor
- Carrick Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Dallas, Texas • San Antonio, Texas • Fairfax, Virginia
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Thrombocytopenia
- Interventions
- romiplostim
- Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Interventions
- HLX17, US-sourced Keytruda®
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more